kabutan

KYORIN Pharmaceutical Co.,Ltd.(4569) Summary

4569
TSE Prime
KYORIN Pharmaceutical Co.,Ltd.
1,558
JPY
-2
(-0.13%)
Apr 28, 3:30 pm JST
9.78
USD
Apr 28, 2:30 am EDT
Result
PTS
outside of trading hours
Summary Chart Historical News Financial Result
PER
18.6
PBR
0.64
Yield
3.66%
Margin Trading Ratio
68.88
Stock Price
Apr 28, 2026
Opening Apr 28, 9:00 am
1,558 JPY 9.77 USD
Previous Close Apr 27
1,560 JPY 9.78 USD
High Apr 28, 9:00 am
1,566 JPY 9.82 USD
Low Apr 28, 12:30 pm
1,548 JPY 9.70 USD
Volume
116,000
Trading Value
0.18B JPY 1.13M USD
VWAP
1554.95 JPY 9.77 USD
Minimum Trading Value
155,800 JPY 978 USD
Market Cap
0.09T JPY 0.59B USD
Number of Trades
328
Liquidity & Number of Trades
As of Apr 28, 2026
Liquidity
Mid
1-Year Average
329
1-Year High Mar 4, 2026
879
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 24, 2026 94,500 101,200 1.07
Apr 17, 2026 85,100 95,800 1.13
Apr 10, 2026 69,500 94,700 1.36
Apr 3, 2026 58,100 82,800 1.43
Mar 27, 2026 66,500 77,900 1.17
Company Profile
KYORIN Pharmaceutical Co., Ltd. is a mid-tier pharmaceutical company. Its main products include asthma medications and expectorants. The company also produces generic drugs and gastrointestinal medicines.
Sector
Pharmaceuticals
KYORIN Pharmaceutical Co., Ltd. primarily engages in the manufacture and sale of pharmaceuticals. The company focuses on prescription drugs such as asthma medications and expectorants, while also having a track record in generic drugs and COVID-19 detection reagents. With manufacturing and sales companies within its group, KYORIN has established an integrated business structure. The company procures some pharmaceutical raw materials from its affiliated companies. In recent years, KYORIN has undergone group restructuring, including the absorption and merger of wholly-owned subsidiaries, to improve management efficiency and accelerate decision-making processes. While adapting to changing medical needs, the company is also concentrating on developing new drugs using its proprietary drug discovery technologies.